MRI contrast-enhancing agents

DRUG4 trials

Sponsors

Sanofi, Shanghai Gynecologic Oncology Group, Medical University of Vienna

Conditions

DLBCL - Diffuse Large B Cell LymphomaMultiple SclerosisOvarian Cancer (OvCa)Ovarian Cancer Metastatic

Early Phase 1

ImmunoMRI for Assessment of Tumor-associated Macrophages

Not yet recruitingNCT07066436

Medical University of ViennaDLBCL - Diffuse Large B Cell Lymphoma

Start: 2025-10-31End: 2028-09-30Target: 60Updated: 2025-07-15

Phase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

RecruitingNCT06141486

SanofiMultiple Sclerosis

Start: 2023-12-27End: 2028-03-24Target: 900Updated: 2026-02-23

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

RecruitingNCT06141473

SanofiMultiple Sclerosis

Start: 2023-12-13End: 2027-05-06Target: 1600Updated: 2026-03-05

Unknown Phase

O-RADS MRI System on Early Detection of Ovarian Cancer

Active, not recruitingNCT07009743

Shanghai Gynecologic Oncology GroupOvarian Cancer Metastatic, Ovarian Cancer (OvCa)

Start: 2025-01-01End: 2028-12-31Target: 2549Updated: 2025-06-08

Related Papers

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials

Neurology2025-04-214 citations